Structural basis for Aβ1-42 toxicity inhibition by Aβ C-terminal fragments: Discrete molecular dynamics study

Journal of Molecular Biology

Volumn 410, Issue 2, 2011, Pages 316-328

  Urbanc, B ^a   Betnel, M ^b   Cruz, L ^a   Li, H ^c   Fradinger, E A ^c,e   Monien, B H ^c,f   Bitan, G ^c,d  

^a DREXEL UNIVERSITY   (United States)

^b Boston University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WHITTIER COLLEGE   (United States)

^f GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

amyloid protein assembly; coarse grained protein model; discrete molecular dynamics; structure toxicity relationship; toxicity inhibitors

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[21-30]; OLIGOMER; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR DYNAMICS; NEUROTOXICITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN STRUCTURE;

EID: 79958703402     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.05.021     Document Type: Article

References (59)

1. Hardy, J. & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353-356. (Pubitemid 34790756)
2. Kirkitadze, M. D., Bitan, G. & Teplow, D. B. (2002). Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69, 567-577.
3. Klein, W. L. (2002). ADDLs & protofibrils - the missing links? Neurobiol. Aging, 23, 231-233.
4. Hardy, J. (2003). Alzheimer's disease: genetic evidence points to a single pathogenesis. Ann. Neuro. 54, 143-144.
5. Klein, W. L., Stine, W. B. & Teplow, D. B. (2004). Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging, 25, 569-580.
6. Glabe, C. G. (2005). Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem. 38, 167-177.
7. Roychaudhuri, R., Yang, M., Hoshi, M. M. & Teplow, D. B. (2008). Amyloid β-protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749-4753.
8. Rahimi, A., Shanmugam, A. & Bitan, G. (2008). Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr. Alzheimer Res. 5, 319-341.
9. Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A. & LaDu, M. J. (2002). Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046-32053.
10. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32, 4693-4697. (Pubitemid 23162022)
11. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. (1993). The C-terminus of the β protein is critical in amyloidogenesis. Ann. N. Y. Acad. Sci. 695, 144-148.
12. Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M. P. et al. (2000). Mutant presenilin 2 transgenicmice. A large increase in the levels of Aβ 42 is presumably associated with the lowdensity membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J. Biol. Chem. 275, 27901-27908.
13. Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B. & Teplow, D. B. (2003). Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA, 100, 330-335.
14. Bernstein, S. L., Wyttenbach, T., Baumketner, A., Shea, J. E., Bitan, G., Teplow, D. B. et al. (2005). Amyloid β-protein: monomer structure and early aggregation states of Aβ42 and its Pro19 alloform. J. Am. Chem. Soc. 127, 2075-2084.
15. Bernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G. et al. (2009). Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat. Chem. 1, 326-331.
16. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E. et al. (2003). Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA, 100, 10417-10422.
17. 1-42 oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95, 834-847.
18. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A. et al. (2006). A specific amyloid-β protein assembly in the brain impairs memory. Nature, 440, 352-357.
19. Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S. et al. (2010). Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol. 17, 561-567.
20. Urbanc, B., Borreguero, J. M., Cruz, L. & Stanley, H. E. (2006). Ab initio discrete molecular dynamics approach to protein folding and aggregation. Methods Enzymol. 412, 314-338. (Pubitemid 44548588)
21. Urbanc, B., Cruz, L., Ding, F., Sammond, D., Khare, S., Buldyrev, S. V. et al. (2004). Molecular dynamics simulation of amyloid β dimer formation. Biophys. J. 87, 2310-2321. (Pubitemid 41071332)
22. Urbanc, B., Cruz, L., Yun, S., Buldyrev, S. V., Bitan, G., Teplow, D. B. et al. (2004). In silico study of amyloid β-protein folding and oligomerization. Proc. Natl Acad. Sci. USA, 101, 17345-17350.
23. Yun, S., Urbanc, B., Cruz, L., Bitan, G., Teplow, D. B. & Stanley,H. E. (2007). Role of electrostatic interactions in amyloid β-protein (Aβ) oligomer formation: a discrete molecular dynamics study. Biophys. J. 92, 4064-4077. (Pubitemid 46910591)
24. Lam, A., Teplow, D. B., Stanley, H. E. & Urbanc, B. (2008). Effects of the arctic (E22→G) mutation on amyloid β-protein folding: discrete molecular dynamics study. J. Am. Chem. Soc. 130, 17413-17422.
25. Urbanc, B., Betnel, M., Cruz, L., Bitan, G. & Teplow, D. B. (2010). Elucidation of amyloid β-protein oligomerization mechanisms: discrete molecular dynamics study. J. Am. Chem. Soc. 132, 4266-4280.
26. Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C. & Teplow, D. B. (2005). On the nucleation of amyloid β-protein monomer folding. Protein Sci. 14, 1581-1596. (Pubitemid 41007920)
27. Murakami, K., Irie, K., Ohigashi, H., Hara, H., Nagao, M., Shimizu, T. et al. (2005). Formation and stabilization model of the 42-mer Aβ radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J. Am. Chem. Soc. 127, 15168-15174.
28. 1-42 Peptide Variants to Elucidate the ADDL Oligomerization Pathway and Conformational Specificity Of Anti-ADDL Antibodies 2006 Neuroscience Meeting Planner, Society for Neuroscience, Atlanta, GA; Program No. 509.5.
29. Yan, Y. & Wang, C. (2006). Aβ42 is more rigid than Aβ40 at the C terminus: implications for Aβ aggregation and toxicity. J. Mol. Biol. 364, 853-862.
30. Sgourakis, N., Yan, Y., McCallum, S., Wang, C. & Garcia, A. (2007). The Alzheimer's peptides Aβ40 and 42 adopt distinct conformations in water: a combined MD/NMR study. J. Mol. Biol. 368, 1448-1457.
31. Streltsov, V., Varghese, J., Masters, C. & Nuttall, S. (2011). Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J. Neurosci. 31, 1419-1426.
32. Fradinger, E., Monien, B. H., Urbanc, B., Lomakin, A., Tan, M., Li, H. et al. (2008). C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proc. Natl Acad. Sci. USA, 105, 14175-14180.
33. Li, H., Monien, B. H., Fradinger, E. A., Urbanc, B. & Bitan, G. (2010). Biophysicsl characterization of Aβ42 C-terminal fragments: inhibitors of Aβ42 neurotoxicity. Biochemistry, 49, 1259-1267.
34. Wu, C., Murray, M. M., Bernstein, S. L., Condron, M. M., Bitan, G., Shea, J. et al. (2009). The structure of Aβ42 C-terminal fragments probed by a combined experimental and theoretical study. J. Mol. Biol. 387, 492-501.
35. Li, H., Monien, B. H., Lomakin, A., Zemel1, R., Fradinger, E. A., Tan, M. et al. (2010). Mechanistic Investigation of the inhibition of Aβ42 assembly and neurotoxicity by c-terminal Aβ42 fragments. Biochemistry, 49, 6358-6364.
36. McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P. & Fraser, P. E. (2000). Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit Aβ-induced toxicity. J. Biol. Chem. 275, 18495-18502.
37. McLaurin, J., Kierstead, M., Brown, M., Hawkes, C., Lambermon, M., Phinney, A. et al. (2006). Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808.
38. DaSilva, K., Shaw, J. & McLaurin, J. (2009). Amyloid-β fibrillogenesis: structural insight and therapeutic intervention. Exp. Neurol. 223, 311-321.
39. Ladiwala, A., Lin, J., Bale, S., Marcelino-Cruz, A., Bhattacharya, M., Dordick, J. et al. (2010). Aromatic small molecules remodel toxic soluble oligomers of amyloid β through three independent pathways. J. Biol. Chem. 286, 3209-3218.
40. Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D. et al. (2005). Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814. (Pubitemid 41362059)
41. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R. et al. (2008). EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566.
42. Ladiwala, A., Lin, J., Bale, S., Marcelino-Cruz, A., Bhattacharya, M., Dordick, J. et al. (2010). Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J. Biol. Chem. 285, 24228-24237.
43. Teplow, D. B., Lazo, N. D., Bitan, G., Bernstein, S., Wyttenbach, T., Bowers, M. T. et al. (2006). Elucidating amyloid β-protein folding and assembly: a multidisciplinary approach. Acc. Chem. Res. 39, 635-645.
44. Humphrey, W., Dalke, A. & Schulten, K. (1996). VMD: visual molecular dynamics. J. Mol. Graphics, 14, 33-38.
45. Kirkitadze, M. D., Condron, M. M. & Teplow, D. B. (2001). Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312, 1103-1119.
46. Ono, K., Condron, M. M. & Teplow, D. B. (2009). Structure- neurotoxicity relationships of amyloid β-protein oligomers. Proc. Natl Acad. Sci. USA, 106, 14745-14750.
47. Chimon, S., Shaibat, M., Jones, C., Calero, D., Aizezi, B. & Ishii, Y. (2007). Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. Nat. Struct. Mol. Biol. 14, 1157-1164.
48. Wu, J. W., Breydo, L., Isas, J. M., Lee, J., Kuznetsov, Y. G., Langen, R. et al. (2010). Fibrillar oligomers nucleate the oligomerization of monomeric amyloid but do not seed fibril formation. J. Biol. Chem. 285, 6071-6079.
49. 2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 73, 67-75.
50. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I. & Glabe, C. G. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294-17300.
51. D'Andrea, M. R. & Nagele, R. G. (2006). Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Des. 12, 677-684.
52. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J. & Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875. (Pubitemid 46438992)
53. Liu, R., Barkhordarian, H., Emadi, S., Park, C. P. & Sierks, M. (2005). Trehalose differentially inhibits aggregation and neurotoxicity of β-amyloid 40 and 42. Neurobiol. Dis. 20, 74-81.
54. Luheshi, L. M., Tartaglia, G. G., Brorsson, A. C., Pawar, A. P., Watson, I. E., Chiti, F. et al. (2007). Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity. PLoS Biol. 5, e290.
55. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D. & Selkoe, D. J. (2011). Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA, 108, 5819-5824.
56. Rapaport, D. C. (1997). The Art of Molecular Dynamics Simulation. Cambridge University Press, Cambridge, UK.
57. Smith, A. V. & Hall, C. K. (2001). α-Helix formation: discontinuousmolecular dynamics on an intermediateresolution proteinmodel. Proteins: Struct., Funct., Genet. 44, 344-360.
58. Ding, F., Borreguero, J. M., Buldyrev, S. V., Stanley, H. E. & Dokholyan, N. V. (2003). Mechanism for the α-helix to β-hairpin transition. Proteins: Struct., Funct., Genet. 53, 220-228.
59. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H. et al. (2000). The Protein Data Bank. Nucleic Acids Res. 28, 235-242. http://www.rcsb.org/pdb. (Pubitemid 30047768)